Command Palette

Search for a command to run...

HESTERBIO
1603.7(-1.59%)
1W: +0.50%

Hester Biosciences Peer Comparison

Snapshot Summary

Hester Biosciences Ltd. demonstrates moderate growth and profitability metrics compared to its peers. While it has a respectable debt-to-equity ratio, it trails behind top performers in revenue growth and efficiency. Value picks are identified among peers with better margins and lower valuation metrics, while several companies exhibit financial weaknesses.

  • • Hester Biosciences has moderate EPS growth but lower revenue growth compared to peers.
  • • Cipla Ltd. emerges as a strong value pick with lower valuation metrics and decent profitability.
  • • Divi's Laboratories and Sun Pharma are identified as financially stressed with high valuations and lower growth rates.
  • • Cipla Ltd.: Strong profitability metrics (ROE of 16.63%) and attractive valuation with a low PE of 23.73.
  • • Mankind Pharma Ltd.: Highest revenue growth YoY (18.12%) and robust profitability metrics.
  • • Dr. Reddy's Laboratories Ltd.: Strong EPS growth and low valuation metrics with a PE of 15.50.
Stock
CMP
Market Cap
P/E
ROE (%)
ROCE (%)
Debt/Equity
HESTERBIO₹1,629.60₹1,388.19Cr36.939.51%9.93%0.66
SUNPHARMA₹1,706.40₹4,09,626.46Cr39.4916.16%19.89%0.03
DIVISLAB₹6,804.00₹1,80,668.62Cr78.3515.35%20.45%0.00
CIPLA₹1,511.50₹1,22,102.70Cr22.4416.63%22.77%0.01
TORNTPHARM₹3,628.30₹1,20,456.12Cr60.1726.46%27.32%0.40
DRREDDY₹1,196.00₹99,965.86Cr17.3218.61%23.25%0.14
ZYDUSLIFE₹981.05₹98,057.50Cr21.4521.08%26.06%0.13

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.

Explore
Watchlists